tbuckley/cabot-search huggingface dataset:
Adjuvant gemcitabine plus docetaxel followed by 5FU chemoradiation for patients with resected pancreaticobiliary cancers: A single-institution, phase II study.
Authors: May Thet Cho
Journal: Journal of Clinical Oncology (2014)

e22243 Background: RTOG 9704 established adjuvant gemcitabine with chemoradiation as an option for patients with pancreatic cancer. We investigated the feasibility and toxicity profile of gemcitabine and docetaxel followed by concurrent 5FU-based chemoradiation in the adjuvant pancreatic and biliary cancer setting. Methods: After curative-intent resection, eligible patients were treated with 2 cycles of gemcitabine 1,000 mg/m2 and docetaxel at 35 mg/m2 on days 1 and 8 of a 21-day cycle followed by standard 5FU-based chemoradiation with 5FU at 225 mg/m2 continuous infusion throughout radiation. Four weeks after RT, 2 more cycles of gemcitabine and docetaxel were administered. The primary endpoint was severe (> grade 2) toxicities. Secondary endpoints included disease-free survival (DFS) and overall survival (OS). Stopping rules were based on the sequential probability rate method. Results: Fifty patients with pancreaticobiliary cancers were enrolled with a median age of 59 years. 29 patients had resected pancreatic cancer while 21 patients had resected biliary tract cancers. There was 1 death due to pneumonia, and 12.5% of patients experienced grade 3 or greater non-hematologic toxicities and 31% experienced grade 3 or higher hematologic toxicities. Median DFS and OS for patients with pancreatic cancer were 9.6 months and 17.6 months, respectively. Median DFS and OS for patients with resected biliary tract cancer were 12.7 months and 23.8 months respectively. Conclusions: This adjuvant regimen appears to be feasible and tolerable. However, outcomes for patients with pancreatic cancer appear to be inferior than other studies. For patients with curatively resected biliary tract cancer, this regimen is a reasonable option. Clinical trial information: NCT00660699.
Sudden death in a woman with unsuspected idiopathic pulmonary hemosiderosis
Authors: D. J. Di Maio
Journal: JAMA (1968)

Idiopathic pulmonary hemosiderosis is usually thought of as a chronic relapsing disease. Sudden and unexpected death occurred in a 22-year-old woman with this condition. Only one similar case in an adult was found in the literature. Six cases of fulminant idiopathic pulmonary hemosiderosis were also found but were not accepted as sudden and unexpected deaths by the authors. Our case together with the others offers further evidence that the course of the disease may follow no typical pattern.
Abstract B46: Biomechanical preconditioning of circulating tumor cell adhesion during metastasis
Authors: Adrianne Spencer, Zhiying Zhu, Katerina Lee, Jason Lee, Chris Spruell, Chad Williams, Peter Voyvodic, Ashwin Ramaswami, Ning Jiang, Aaron Baker
Journal: Cancer Research (2016)

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR08) of the Conference Proceedings. Citation Format: Adrianne Spencer, Zhiying Zhu, Katerina Lee, Jason Lee, Chris Spruell, Chad Williams, Peter Voyvodic, Ashwin Ramaswami, Ning Jiang, Aaron Baker. Biomechanical preconditioning of circulating tumor cell adhesion during metastasis. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr B46.
Technique chirurgicale oto-rhino-laryngologique.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition
Authors: Nam Hee Kim, Hyun Sil Kim, Xiao-Yan Li, Inhan Lee, Hyung-Seok Choi, Shi Eun Kang, So Young Cha, Joo Kyung Ryu, Dojun Yoon, Eric R. Fearon, R. Grant Rowe, Sanghyuk Lee, Christopher A. Maher, Stephen J. Weiss, Jong In Yook
Journal: The Journal of Experimental Medicine (2011)
Scald burns from hot tap water
Authors: M. L. Katcher
Journal: JAMA (1981)

Hot tap water is a common source of household burn injury. The charts of all patients hospitalized for tap water scalds in Dane County, Wisconsin, during a ten-year period were reviewed. Of 33 patients, 29 (88%) had readily identifiable risk factors: 17 (52%) were children younger than 5 years; three (9%) were older than 65 years; ten (30%) were physically or mentally disabled. One additional person was burned in a nonhome environment. Of the five deaths, three occurred in children younger than 30 months, and two occurred in patients older than 70 years. Almost all of these injuries could have been prevented by lowering the temperature of the household water heater to below 54.4 °C (130 °F) and preferably between 48.9 and 51.7 °C (120 to 125 °F). Physicians can play an important role in the prevention of this type of injury. (<i>JAMA</i>1981;246:1219-1222)
Localization of infectious processes with gallium citrate Ga 67
Authors: D. C. Blair
Journal: JAMA (1974)

Thirty patients received gallium citrate Ga 67 for scintiscanning in a search for abscesses and other covert infections—25 intra-abdominal and 5 extra-abdominal. Abnormal areas of isotope uptake were found in 25 patients; of these, six had proven infections; 15 had clinically established infections (but confirmatory tissue diagnostic procedures were not performed); one scan was false-positive; and three abnormal scans were due to tumor. This noninvasive scanning procedure has proved useful in identifying sites of inflammation. (<i>JAMA</i>230:82-85, 1974)
<i>Treatise on IJiphtheria, Historically and Practically Considered, including Group, Tracheotomy and Intubation</i>. By A. Sanne. Translated and Annotated by H. Z. Gill, A.M., M.D., LL.D. St. Louis: J. H. Chambers &amp; Co., 1887
Journal: American Journal of Psychiatry (1887)
Primary cutaneous histoplasmosis in immunosuppressed patient
Authors: G. R. Cott
Journal: JAMA (1979)

<i>HISTOPLASMA CAPSULATUM</i>may cause several types of cutaneous manifestations. Disseminated histoplasmosis has been most commonly associated with oral mucocutaneous ulcers,<sup>1-3</sup>which may persist longer than three months. The progressive cutaneous form of disseminated histoplasmosis may appear as granulomas, ulcerations, or papulonecrotic lesions. Differentiation of these lesions from other cutaneous ulcers on clinical grounds alone is difficult if not impossible. Etiologic confirmation is determined by isolating<i>H capsulatum</i>, usually from a biopsy specimen. Primary cutaneous histoplasmosis, in which the organism is confined to the skin, is uncommon. To our knowledge, only three verified cases have been reported.<sup>4-6</sup>Furcolow<sup>7</sup>has reviewed previous possible cases. In each of the three verified cases, the infection was self-limited without systemic therapy. The purpose of this report is to present a fourth case of apparent primary cutaneous histoplasmosis. The disease in this immunosuppressed patient differed from previously reported cases of primary cutaneous histoplasmosis in being
Hematologic changes in anorexia nervosa
Authors: P. C. Amrein
Journal: JAMA (1979)

WE RECENTLY encountered a patient with anorexia nervosa who demonstrated pancytopenia, a hypoplastic bone marrow, and notable acanthocytosis. Although this constellation of findings has been reported in anorexia nervosa, to our knowledge, it is not fully described in major textbooks of hematology and has not previously been reported in the American medical literature. In addition, we have further verified the association of acanthocytosis and low levels of β-lipoproteins in a patient with anorexia nervosa. <h3>Report of a Case</h3> An 18-year-old woman had been examined for weight loss and amenorrhea in 1975 and had the diagnosis of anorexia nervosa since that time. She had been hospitalized one week before admission because of worsening anorexia and cachexia. At that time the hematocrit value was 40%, and the WBC count was 3,400/cu mm, with a normal differential cell count. No comment was made about an abnormal RBC morphological condition. Following 12 hours of
MEDICAL FACILITIES OF DETROIT AND PHILADELPHIA AND THE MIGRATORY PHYSICIAN
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FINLAND
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tough Decisions
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 192: Long Term Coronary Angiography of Giant Coronary Aneurysms after Kawasaki Disease in Mexican Children
Authors: Luis M Garrido-Garcia, Jose L Colin, Alfredo Bobadilla-Aguirre
Journal: Circulation (2015)

Kawasaki Disease (KD) is an acute febrile illness characterized by systemic vasculitis of unknown etiology. Coronary artery aneurysms (CAA), is one of the most important aspects of this disease. Some patients with KD develop giant coronary aneurysms (z-score &gt; 10) and coronary stenosis, leading to ischemic heart disease. Objective: To determine the outcome of giant coronary artery lesions caused by KD and the value of coronary angiography in the evaluation and follow-up of coronary artery lesions in Mexican children. Materials and Methods: From our Institutional database, 34 patients (23 men and 11 women) who developed giant aneurysms from 1995 to December 2013 were identified. Information on patient demographics, catheter and surgical interventions, and most recent status was collected from medical records. Results: The average age at onset of KD was 13.5 months, and the median observational period was 70 mo. (5 to 163 mo.). During this period 11 patients showed CAA regression, 21 patients persist with CAA and 2 patients died at follow-up. In 9 patients with persistent giant CAA or coronary stenosis we performed cardiac catheterization to evaluate the coronary anatomy and findings of myocardial ischemia. Coronary bypass was performed to alleviate coronary ischemia in 1 patient, this patient developed dilated cardiomyopathy one year after the surgery and died. The overall survival rate in our series is 97%. Conclusions: Despite being a small series, the long-term survival of patients with KD complicated by giant coronary aneurysms in our center is relatively good. However further research should focus on the indications for and effectiveness of percutaneous and surgical coronary interventions.
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Authors: Michael M. Ward, Atul Deodhar, Lianne S. Gensler, Maureen Dubreuil, David Yu, Muhammad Asim Khan, Nigil Haroon, David Borenstein, Runsheng Wang, Ann Biehl, Meika A. Fang, Grant Louie, Vikas Majithia, Bernard Ng, Rosemary Bigham, Michael Pianin, Amit Aakash Shah, Nancy Sullivan, Marat Turgunbaev, Jeff Oristaglio, Amy Turner, Walter P. Maksymowych, Liron Caplan
Journal: Arthritis & Rheumatology (2019)

Objective To update evidence‐based recommendations for the treatment of patients with ankylosing spondylitis ( AS ) and nonradiographic axial spondyloarthritis (SpA). Methods We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on pharmacologic treatment, treat‐to‐target strategy, and use of imaging. New questions addressed the use of secukinumab, ixekizumab, tofacitinib, tumor necrosis factor inhibitor ( TNF i) biosimilars, and biologic tapering/discontinuation, among others. We used the Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations and required at least 70% agreement among the voting panel. Results Recommendations for AS and nonradiographic axial SpA are similar. TNF i are recommended over secukinumab or ixekizumab as the first biologic to be used. Secukinumab or ixekizumab is recommended over the use of a second TNF i in patients with primary nonresponse to the first TNF i. TNF i, secukinumab, and ixekizumab are favored over tofacitinib. Co‐administration of low‐dose methotrexate with TNF i is not recommended, nor is a strict treat‐to‐target strategy or discontinuation or tapering of biologics in patients with stable disease. Sulfasalazine is recommended only for persistent peripheral arthritis when TNF i are contraindicated. For patients with unclear disease activity, spine or pelvis magnetic resonance imaging could aid assessment. Routine monitoring of radiographic changes with serial spine radiographs is not recommended. Conclusion These recommendations provide updated guidance regarding use of new medications and imaging of the axial skeleton in the management of AS and nonradiographic axial SpA.
Cell Transplantation for the Treatment of Acute Myocardial Infarction Using Vascular Endothelial Growth Factor–Expressing Skeletal Myoblasts
Authors: Ken Suzuki, Bari Murtuza, Ryszard T. Smolenski, Ivan A. Sammut, Noriko Suzuki, Yasufumi Kaneda, Magdi H. Yacoub
Journal: Circulation (2001)

Background Vascular endothelial growth factor (VEGF) is a promising reagent for inducing myocardial angiogenesis. Skeletal myoblast transplantation has been shown to improve cardiac function in chronic heart failure models by regenerating muscle. We hypothesized that transplantation of VEGF-expressing myoblasts could effectively treat acute myocardial infarction by providing VEGF-induced cardioprotection through vasodilatation in the early phase, followed by angiogenesis effects in salvaging ischemic host myocardium combined with the functional benefits of newly formed, skeletal myoblast-derived muscle in the later phase. Methods and Results Primary rat skeletal myoblasts were transfected with the human VEGF 165 gene using hemagglutinating virus of Japan-liposome with &gt;95% transfection efficiency. Four million of these myoblasts (VEGF group), control-transfected myoblasts (control group), or medium only (medium group) was injected into syngeneic rat hearts 1 hour after left coronary artery occlusion. Myocardial VEGF-expression increased for 2 weeks in the VEGF group, resulting in enhanced angiogenesis without the formation of tumors. Grafted myoblasts had differentiated into multinucleated myotubes within host myocardium. Infarct size (33.3±1.4%, 38.1±1.4%, and 43.7±1.6% for VEGF, control, and medium groups, respectively; P =0.0005) was significantly reduced with VEGF treatment, and cardiac function improved in the VEGF group (maximum dP/dt: 4072.0±93.6, 3772.5±101.1, and 3482.5±90.6 mm Hg/s in the 3 groups, respectively; P =0.0011; minimum dP/dt: −504.2±68.5, −2311.3±57.0, and −2124.0±57.9 mm Hg/s, respectively; P =0.0008). Conclusions This combined strategy of cell transplantation with gene therapy could be of importance for the treatment of acute myocardial infarction.
Combination chemotherapy with paclitaxel and platinum in the treatment for advanced or recurrent ovarian clear cell adenocarcinoma: Multicenter trial
Authors: K. Ota, J.-I. Akahira, H. Utsunomiya, T. Takano, H. Niikura, K. Ito, N. Yaegashi
Journal: Journal of Clinical Oncology (2004)

5101 Background: Patients with clear cell adenocarcinoma of the ovary (CC) have a poor response to chemotherapy and have a significantly worse prognosis than other histological types of ovarian cancer. However, the therapeutic effect of a combination of paclitaxel (PTX) and platinum (PLT) in CC patients with measurable disease has yet to be elucidated. In this study, we evaluated the treatment results of a combination of PTX and PLT in CC patients with measurable disease by retrospective review. Methods: Twenty–eight patients with measurable residual CC (12 primary cases and 16 recurrent cases), who were treated with combination chemotherapy with PTX and PLT, were identified through the medical records from 10 institutions. Patients with serous adenocarcinoma were selected as a control for comparison. Histological evaluation was performed under the central pathological review. Clinical response to chemotherapy was compared between CC and serous adenocarcinoma patients using RECIST criteria. Results: In primary cases, 7 of 12 CC patients (58.3%) and 17 of 22 serous adenocarcinoma patients (77.3%) responded to chemotherapy, and the difference was not significant. In recurrence CC cases, 3 of 16 CC patients (18.8%) responded to the chemotherapy. The difference of response rate between primary and recurrent cases in CC patients was statistically significant (P<0.05). Conclusion: The response rate of this combination chemotherapy for primary residual CC patients was relatively high and was comparable with those of serous adenocarcinoma. Our results indicate that the combination of PTX and PLT has a sufficient potential as first–line chemotherapy to this 'assumed' chemo–resistant tumor. No significant financial relationships to disclose.
Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low regimen
Journal: Annals of the Rheumatic Diseases (1976)

the increasing sophistication of way of life (Popert and Hewitt, 1962;Rose and Prior, 1963).A further step will be to study the relationship between SUA concentrations and common disease processes, which also have a changing prevalence.Similarly, potential environmental determinants of SUA concentrations will be selected for scrutiny to establish the extent of their influence upon this course ofevents.
Phenotypic variation among myeloid-derived suppressor cells (MDSC) in natural history phases of chronic HBV infection differentially impacts HBV-specific T cell response and homing: lack of functional normalization after anti-viral therapy
Authors: Sourina Pal, Debangana Dey, Madhuparna Nandi, Archi Goswami, Mousumi Khatun, Soma Banerjee, Amal K Santra, Sk. Mahiuddin Ahammed, Abhijit Chowdhury, Simanti Datta
Journal: Journal of Hepatology (2020)
Guidelines for the Physician Expert Witness
Journal: Annals of Internal Medicine (1990)

Editorial Note: The Clinical Practice Subcommittee of the College's Health and Public Policy Committee undertook development of "Guidelines for the Physician Expert Witness" in order to encourage broad physician participation in providing this much-needed assistance to the legal system. The College believes that more physicians should serve as experts as a component of their professional activities in order to meet the need for medical testimony rather than a few physicians with little current involvement in patient care spending disproportionate amounts of time testifying. The guidelines, adapted from the "Statement on Qualifications and Guidelines for the Physician Expert Witness" by the Council of Medical Specialty Societies (20 March 1989), recommend qualifications for experts and give general guidance.